Brought to you by 
QLT settles Eligard patent dispute; pay-out is $157.5mm
05 Mar 2007
Executive Summary
QLT Inc. (ophthalmology, urology, and dermatology treatments) and its QLT USA subsidiary (formerly Atrix Laboratories) have reached an agreement with TAP Pharmaceutical Products, Takeda Chemical, and Wako Pure Chemical regarding potential patent infringement.
Deal Industry
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
QLT settles Eligard patent dispute; pay-out is $157.5mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice